ABSTRACT The worrisome increase in Gram-negative bacteria with borderline susceptibility to carbapenems and of carbapenemase-producing Enterobacteriaceae has significantly undermined their efficacy. Continuous infusion may be the best way to maximize the time-dependent activity of meropenem. The aim of this study was to create dosing nomograms in relation to different creatinine clearance (CL _Cr ) estimates for use in daily clinical practice to target the steady-state concentrations ( C _ss s) of meropenem during continuous infusion at 8 to 16 mg/liter (after the administration of an initial loading dose of 1 to 2 g over 30 min). The correlation between meropenem clearance (CL _m ) and CL _Cr was retrospectively assessed in a cohort of critically ill patients (group 1, n = 67) to create a formula for dosage calculation to target C _ss . The performance of this formula was validated in a similar cohort (group 2, n = 56) by comparison of the observed and the predicted C _ss s. A significant relationship between CL _m and CL _Cr was observed in group 1 ( r = 0.72, P < 0.001). The application of the formula to meropenem dosing in group 2, infusion rate (g/24 h) = [0.078 × CL _Cr (ml/min) + 2.85] × target C _ss × (24/1,000), led to a significant correlation between the observed and the predicted C _ss s ( r = 0.92, P < 0.001). Dosing nomograms based on CL _Cr were created to target the meropenem C _ss at 8, 12, and 16 mg/liter in critically ill patients. These nomograms could be helpful in improving the treatment of severe Gram-negative infections with meropenem, especially in the presence of borderline susceptible pathogens or even of carbapenemase producers and/or of pathophysiological conditions which may enhance meropenem clearance.